Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

William G. Wierda, MD PhD, Kathleen A. Dorritie, MD, Javier Munoz, MD, Deborah M. Stephens, DO, Scott R. Solomon, MD, Heidi H. Gillenwater, MD, Lucy Gong, PharmD, Lin Yang, PhD, Ken Ogasawara, PhD MPH, Jerill Thorpe, BS, Tanya Siddiqi, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-140622

Published: 2020

Journal Articles

Updated Follow-up of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated with Lisocabtagene Maraleucel in the Phase 1 Monotherapy Cohort of Transcend CLL 004, Including High-Risk and Ibrutinib-Treated Patients

Tanya Siddiqi, MD, Jacob D. Soumerai, MD, Kathleen A. Dorritie, MD, Deborah M. Stephens, DO, Peter A. Riedell, MD, Jon E. Arnason, MD, Thomas J. Kipps, MD PhD, Heidi H. Gillenwater, MD, Lucy Gong, PharmD, Lin Yang, PhD, Ken Ogasawara, PhD MPH, William G. Wierda, MD PhD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-140491

Published: 2020

Journal Articles

Pretreatment Next-Generation Sequencing Is Associated with Response to Induction Chemotherapy in Patients Newly Diagnosed with Acute Myeloid Leukemia

Anastasia Tsagianni, MD, Konstantinos Lontos, MD, Mounzer Agha, MD, Anastasios Raptis, MD, Jing-Zhou Hou, MD PhD, Rafic J. Farah, MD, Robert L. Redner, MD, Annie Im, MD, Kathleen A. Dorritie, MD, Alison R. Sehgal, MD, James M. Rossetti, DO, Melissa Saul, MS, William Gooding, MS, Michael Boyiadzis, MD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-138561

Published: 2020

Journal Articles

Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib

Tanya Siddiqi, MD, Jacob D. Soumerai, MD, Kathleen A. Dorritie, MD, Deborah M. Stephens, DO, Peter A. Riedell, MD, Jon E. Arnason, MD, Thomas J. Kipps, MD PhD, Heidi H. Gillenwater, MD, Lucy Gong, PharmD, Jason A. Dubovsky, PhD, Julie Rytlewski, PhD, Lin Yang, William G. Wierda, MD PhD

Blood (2019) 134 (Supplement_1): 503.

https://doi.org/10.1182/blood-2019-127603

Published: 2019

Journal Articles

Higher Number of Cycles of Cytarabine Consolidation Improves Outcomes in Elderly AML Patients

Asha Ricciuti, MD, Mounzer Agha, MD, Anastasios Raptis, MD, Jing-Zhou Hou, MD PhD, Rafic Farah, MD, Robert L. Redner, MD, Alison R. Sehgal, MD, Kathleen A. Dorritie, MD, James M. Rossetti, DO, Yongli Shuai, PhD, Daniel Normolle, PhD, Rahim Remtulla, MD, Shawn Tahata, MD, Michael Boyiadzis, MD, Annie Im, MD

Blood (2018) 132 (Supplement 1): 4000.

https://doi.org/10.1182/blood-2018-99-113935

Published: 2018

Journal Articles

Rapid MRD-Negative Responses in Patients with Relapsed/Refractory CLL Treated with Liso-Cel, a CD19-Directed CAR T-Cell Product: Preliminary Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib

Tanya Siddiqi, MD, Jacob D. Soumerai, MD, William G. Wierda, MD PhD, Jason A. Dubovsky, PhD, Heidi H. Gillenwater, MD, Lucy Gong, PharmD, Alan Mitchell, MSc, Jerill Thorpe, BSc, Lin Yang, PhD, Kathleen A. Dorritie, MD

Blood (2018) 132 (Supplement 1): 300.

https://doi.org/10.1182/blood-2018-99-110462

Published: 2018

Journal Articles

Location Matters in Nodal Diffuse Large B-Cell Lymphoma

Konstantinos Lontos, MD, Anastasia Tsagianni, MD, Swathi Namburi, Arpita Gandhi, MD BA, Jian-Min Yuan, MD PhD, Daniel Normolle, PhD, Michael Boyiadzis, MD, Steven H. Swerdlow, MD, Kathleen A. Dorritie, MD

Blood (2017) 130 (Supplement 1): 2854.

https://doi.org/10.1182/blood.V130.Suppl_1.2854.2854

Published: 2017

Journal Articles

Phase 1 Clinical Trial of Adoptive Immunotherapy Using "Off-the-Shelf" Activated Natural Killer Cells (aNK) in Patients with Refractory/Relapsed Acute Myeloid Leukemia

Michael Boyiadzis, MD MHSc, Mounzer Agha, MD, Robert L Redner, MD, Alison Sehgal, MD, Annie Im, MD, Jing-Zhou Hou, Rafic Farah, MD, Kathleen A. Dorritie, MD, Anastasios Raptis, MD PhD, Seah H. Lim, MDPhDFRCP,FRCPath,MBBS, Hans Klingemann, MD PhD, Hong Wang, PhD, Natalia Lapteva, PhD, Mei Zhuyong, MD, Lisa H Butterfield, PhD, Cliona M. Rooney, PhD, Theresa L Whiteside, PhD

Blood (2016) 128 (22): 1649.

https://doi.org/10.1182/blood.V128.22.1649.1649

Published: 2016

Journal Articles

Phase 2 Study of Epigenetic Priming Using Decitabine Followed By Cytarabine As an Induction Regimen in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

Annie Im, MD, Mounzer Agha, MD, Anastasios Raptis, MD PhD, Jing-Zhou Hou, MD PhD, Rafic Farah, MD, Seah H. Lim, MDPhDFRCP,FRCPath,MBBS, Robert Redner, MD, Alison R. Sehgal, MD, Kathleen A. Dorritie, MD, Ann Welsh, RN, BSN, OCN, Linda Fukas, RN, Christine Tripoli, RN, BSN, Daniel Normolle, PhD, Daniel E Johnson, PhD, Michael Boyiadzis, MD MHSc

Blood (2015) 126 (23): 3739.

https://doi.org/10.1182/blood.V126.23.3739.3739

Published: 2015

Journal Articles

Epigenetic Priming Using Decitabine Followed By Cytarabine As an Induction Regimen in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

Annie Im, MD, Jing-Zhou Hou, MD PhD, Anastasios Raptis, MD, Mounzer Agha, MD, Rafic Farah, MD, Robert L. Redner, MD, Alison R. Sehgal, MD, Kathleen A. Dorritie, MD, Ann Welsh, RN, Daniel E. Johnson, PhD, Daniel Normolle, PhD, Michael Boyiadzis, MD

Blood (2014) 124 (21): 2265.

https://doi.org/10.1182/blood.V124.21.2265.2265

Published: 2014

NARROW

Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Updated Follow-up of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated with Lisocabtagene Maraleucel in the Phase 1 Monotherapy Cohort of Transcend CLL 004, Including High-Risk and Ibrutinib-Treated Patients

Pretreatment Next-Generation Sequencing Is Associated with Response to Induction Chemotherapy in Patients Newly Diagnosed with Acute Myeloid Leukemia

Higher Number of Cycles of Cytarabine Consolidation Improves Outcomes in Elderly AML Patients

Rapid MRD-Negative Responses in Patients with Relapsed/Refractory CLL Treated with Liso-Cel, a CD19-Directed CAR T-Cell Product: Preliminary Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib

Location Matters in Nodal Diffuse Large B-Cell Lymphoma

Phase 1 Clinical Trial of Adoptive Immunotherapy Using "Off-the-Shelf" Activated Natural Killer Cells (aNK) in Patients with Refractory/Relapsed Acute Myeloid Leukemia

Phase 2 Study of Epigenetic Priming Using Decitabine Followed By Cytarabine As an Induction Regimen in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

Epigenetic Priming Using Decitabine Followed By Cytarabine As an Induction Regimen in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only